Dr. Longsworth is a director in the Biotechnology/Chemical Group and has significant experience in counseling clients on issues of patentability, freedom to operate, and infringement, including analyzing multi-patent portfolios for marketed pharmaceutical products. She has also represented clients in patent reexamination and opposition proceedings, written and prosecuted patent applications, and prepared hundreds of invalidity, noninfringement, freedom-to-operate, and patentability opinions. Dr. Longsworth also has extensive experience in FDA/ANDA practice and has been involved in multiple pharmaceutical patent litigations brought under the Hatch-Waxman Act.
Additionally, Dr. Longsworth is experienced in procuring or investigating patents related to, genes and gene expression systems, proteins, antibodies, vaccines, small molecules, chemical synthesis, pharmaceutical formulations (capsules, tablets, orally disintegrating dosage forms, transdermal patches, injectables, ophthalmics, creams, gels, suspensions, and nasal and oral inhalation forms), drug delivery devices, and methods of treatment with pharmaceuticals.
While at Johns Hopkins, Dr. Longsworth was the recipient of a Predoctoral Minority Fellowship from the National Institute of General Medical Sciences. Dr. Longsworth’s graduate research involved the generation and analysis of a collection of trafficking defective Ste6p mutants and the implications for the process of ER quality control in Saccharomyces cerevisiae. Ste6p is a member of the ATP Binding Cassette (ABC) family that use ATP to transport a wide range of substrates into and out of cells and between cellular compartments. Clinically important mammalian ABC proteins include the mammalian drug resistance protein (MDR) and the cystic fibrosis transmembrane conductance regulator (CFTR). Dr. Longsworth is fluent in Dutch and she also serves on the Reexamination Center Editorial Board.
Technical Publications
Huyer G, Longsworth GL, Mason DL, Mallampalli MP, McCaffery JM, Wright RL, Michaelis S. "A striking quality control subcompartment in Saccharomyces cerevisiae: the endoplasmic reticulum-associated compartment." Mol Biol Cell. 15(2):908-21 (2004).
Zhang, Y., Nijbroek, G., Sullivan, M.L., McCracken, A.A., Watkins, S.C., Michaelis, S. and Brodsky, J.L. "Hsp70 molecular chaperone facilitates endoplasmic reticulum-associated protein degradation of cystic fibrosis transmembrane conductance regulator in yeast". Mol. Biol. Cell. 12(5):1303-14 (2001).
Nijbroek, G.L. and Michaelis, S. "Functional assays for analysis of yeast ste6 mutants." Methods Enzymol. 292:193-212 (1998).
Brizzio, V., Gammie, A.E., Nijbroek, G., Michaelis, S. and Rose, M.D. "Cell fusion during yeast mating requires high levels of a-factor mating pheromone." J. Cell Biol. 135(6 Pt 2):1727-39 (1996).
Nijbroek, G., Sood, S., McIntosh, I., Francomano, C.A., Bull, E., Pereira, L., Ramirez, F., Pyeritz, R.E. and Dietz, H.C. "Fifteen novel FBN1 mutations causing Marfan syndrome detected by heteroduplex analysis of genomic amplicons." Am. J. Hum. Genet. 57(1):8-21 (1995).
RSS
twitter